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ABSTRACT
Objectives Plasmacytoid dendritic cells (pDC) have 
been implicated in the pathogenesis of autoimmune 
diseases, such as scleroderma (SSc). However, this has 
been derived from indirect evidence using ex vivo human 
samples or mouse pDC in vivo. We have developed 
human- specific pDC models to directly identify their role 
in inflammation and fibrosis, as well as attenuation of 
pDC function with BDCA2- targeting to determine its 
therapeutic application.
Methods RNAseq of human pDC with TLR9 agonist 
ODN2216 and humanised monoclonal BDCA2 antibody, 
CBS004. Organotypic skin rafts consisting of fibroblasts 
and keratinocytes were stimulated with supernatant 
from TLR9- stimulated pDC and with CBS004. Human 
pDC were xenotransplanted into Nonobese diabetic/
severe combined immunodeficiency (NOD SCID) mice 
treated with Aldara (inflammatory model), or bleomycin 
(fibrotic model) with CBS004 or human IgG control. Skin 
punch biopsies were used to assess gene and protein 
expression.
Results RNAseq shows TLR9- induced activation 
of human pDC goes beyond type I interferon (IFN) 
secretion, which is functionally inactivated by BDCA2- 
targeting. Consistent with these findings, we show 
that BDCA2- targeting of pDC can completely suppress 
in vitro skin IFN- induced response. Most importantly, 
xenotransplantation of human pDC significantly 
increased in vivo skin IFN- induced response to TLR 
agonist and strongly enhanced fibrotic and immune 
response to bleomycin compared with controls. In these 
contexts, BDCA2- targeting suppressed human pDC- 
specific pathological responses.
Conclusions Our data indicate that human pDC play a 
key role in inflammation and immune- driven skin fibrosis, 
which can be effectively blocked by BDCA2- targeting, 
providing direct evidence supporting the development of 
attenuation of pDC function as a therapeutic application 
for SSc.
INTRODUCTION
Plasmacytoid dendritic cells (pDC), specialised in 
the secretion of type I interferon (IFN),1–3 activate 
inflammatory responses through TLR- mediated 
sensing of nucleic acids released from pathogens 
during infection or following cell death in autoim-
munity.4–8 Self- derived nucleic acids released from 
damaged tissues, apoptotic/necrotic cells or bound 
to autoantibodies, can be recognised by TLR7/8/9 
and have been shown to induce pDC activation 
and IFN secretion.9–15 The role of CXCL4 has been 
elucidated as an amplifier of TLR9- mediated pDC 
hyperactivation and IFN production by organ-
ising self- DNA into liquid crystalline immune 
complexes.16
TLR- induced activation of pDC triggers stable 
cell differentiation into three subtypes, with 
Key messages
What is already known about this subject?
 ► Research to date on plasmacytoid dendritic cells 
(pDC) has focused only on indirect evidence 
using ex vivo human samples or mouse models, 
but suggests pDC involvement in interferon 
(IFN)- induced response, skin infiltration and 
fibrosis within immune- mediated inflammatory 
disease (IMID), such as scleroderma.
What does this study add?
 ► We devised a novel mouse model of human 
pDC through xenotransplantation of human 
pDC into immunocompromised mice, showing a 
significantly increased IFN- induced response to 
topical TLR agonist application and a strongly 
enhanced fibrotic and immune response 
to bleomycin, all of which were strongly 
suppressed by specific pDC BDCA2- targeting.
 ► We demonstrate directly that functional 
inactivation of human pDC through BDCA2- 
targeting suppresses the entire TLR9- induced 
transcriptome, which includes type I IFN 
activation and a multitude of genes that could 
contribute to immune- driven tissue damage.
How might this impact on clinical practice or 
future developments?
 ► These data offer the first direct evidence 
supporting the development of BDCA2- 
targeting as a therapeutic application for pDC- 
mediated skin inflammation and fibrosis.
 ► The development of a human pDC mouse model 
will allow the expansion into other IMID to 
confirm pDC involvement.
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PD- L1(CD274)+CD80− (P1) and PD- L1+CD80+ (P2) subpop-
ulations specialised in type I IFN production both in healthy 
volunteers (HV) and patients with autoimmune conditions.17 
pDC have been further implicated in the pathogenesis of autoim-
mune diseases, such as scleroderma (SSc), systemic lupus erythe-
matosus (SLE) and psoriasis, through their ability to infiltrate the 
skin and secrete IFNs and proinflammatory chemokines.13 18–22 
Specifically, SSc is an immune- mediated inflammatory disease 
(IMID) characterised by vascular and tissue fibrosis, leading to 
diverse life- altering and life- threatening clinical manifestations.23 
pDC have been observed in affected skin of patients with SSc, and 
purified peripheral SSc pDC have been shown to spontaneously 
produce higher levels of type I IFN compared with HV.24–26 
Indeed, an elevated IFN gene signature in affected organs and 
in the blood is a common feature of severe disease in SSc,25 27 
which is present before the onset of clinical fibrosis.28 These 
observations collectively support the notion that pDC activation 
and type I IFN play an important role in SSc pathogenesis.
BDCA2 is a type II transmembrane glycoprotein that belongs 
to the C- type lectin superfamily receptor that can signal to 
inhibit pDC type I IFN secretion.2 29–31 BDCA2 signals through 
an associated transmembrane adaptor, the FcϵRγ, which recruits 
the protein tyrosine kinase Syk, inducing protein tyrosine phos-
phorylation and calcium mobilisation,32 which reduces TLR- 
induced activation of pDC, inhibiting type I IFN secretion and 
other inflammatory mediators.30 32–34 In SLE clinical trials, 
BDCA2- targeting antibodies induced a significant but partial 
decrease in IFN response within the blood, and reduced type I 
IFN- induced response and immune infiltrates in skin lesions.35 36 
Recently, pDC’s role in fibrosis was elucidated as elimination of 
mouse pDC reduced bleomycin- induced skin fibrosis,24 further 
highlighting the therapeutic potential of BDCA2- targeting for 
SSc. However, exploring the efficacy of BDCA2- targeting during 
fibrosis is difficult, as BDCA2 is only expressed in primates, 
highlighting the need for a human- specific pDC in vivo model. 
Furthermore, there are key differences between mouse and 
human pDC; thus, functions determined in mouse models may 
not be fully transferable to human pDC.13 37–39
We developed human- specific models to uncover the role of 
pDC biology in inflammation and fibrosis, as well as attenuation 
of pDC function with BDCA2- targeting to determine its thera-
peutic application for SSc.
RESULTS
TLR9-induced activation of human pDC goes beyond type I 
IFN secretion and is hindered by BDCA2-targeting
Using RNAseq, we set out to discover the transcriptome of 
human pDC when stimulated with TLR9 agonist, A- class 
oligodeoxyribonucleotides containing CpG motifs (ODN2216/
ODN), to understand the pathways that could contribute to 
the pathogenesis of chronic inflammation and immune- driven 
tissue damage seen in IMID. We performed RNAseq analysis of 
human pDC purified from peripheral blood mononuclear cells 
(PBMC) from four HV (online supplemental figure S1), as previ-
ously described.34 Transcriptome analysis revealed 328 differen-
tially expressed genes (DEGs ≥or ≤2 fold change, FDR≤0.05) 
between unstimulated (control/CTR) and ODN- stimulated pDC 
(ODN), with donor heterogeneity observed with ODN stimula-
tion, suggesting pDC response donor variability (figure 1A and 
online supplemental table 1). Pathway analysis identified genes 
involved in immune response against viruses and other organ-
isms as key enriched biological processes (figure 1B). These 
innate immune processes match to those previously identified 
in characterised inflammatory SSc skin subsets,40 suggesting 
involvement of pDC activation in this specific subset. Consistent 
with this notion, we observed upregulation of many type I IFN- 
dependent pathways and IFN- related genes, such as IFN- A2, 
IFN- A21, IFN- B1 and CCL5, a common feature seen in SSc.40–42 
Pathway analysis also showed JAK/STAT, nuclear factor kappa B 
subunit 1 (NF-κB) and angiogenesis pathways to be major biolog-
ical processes upregulated by ODN stimulation (figure 1B), 
which have been shown to be dysregulated in SSc13 40 41 but not 
shown in pDC before. These data suggest that TLR stimulation 
of pDC can induce a multitude of genes beyond IFN, which 
could contribute to the pathogenesis of inflammation in SSc and 
other IMID. Interestingly, a recent publication showed that the 
majority of SSc skin samples with higher fibroblast scores had 
significantly increased macrophage and/or dendritic cell scores, 
suggesting a link between the two cell types that are important 
for inducing the fibroinflammatory signature.41
A monoclonal BDCA2 antibody (clone AC144) has previously 
been shown to suppress human pDC TLR- induced IFN type I 
secretion by interfering with the FcϵRγ-Syk signalling.19 30 To aid 
our understanding of human pDC in IMID, we generated mouse 
monoclonal antibodies (mAb) against human BDCA2 and fully 
humanised the lead mAb, CBS004, which had a greater affinity 
for BDCA2 compared with AC144 control (online supplemental 
figure S2A). Ex vivo direct competition assays showed that 
CBS004 and AC144 bind alternative pDC epitopes, as indicated 
by double staining of the pDC population gated within PBMC 
(LIN− HLA+ CD123+ CD304+) (online supplemental figure 
S2B,C).
BDCA2- targeting using CBS004 reduced the expression of 60% 
of ODN- inducible DEGs ≥1.5- fold (figure 1C and online supple-
mental table 2). It has been recently shown that TLR- induced 
pDC triggers stable cell differentiation into three stable subtypes, 
with PD- L1(CD274)+CD80− (P1) and PD- L1(CD274)+CD80+ 
(P2) subpopulations specialised in type I IFN production both 
in HV and patients with autoimmune conditions.17 Consistent 
with these observations, ODN induced CD274 expression, 
which was also suppressed by BDCA2- targeting (figure 1C).17 
To validate the RNAseq findings at protein level, we measured 
the PD- L1 and CD80 positive subpopulations by fluorescence- 
activated cell sorting (FACS) (figure 1D,E). Similarly to what 
has been observed following viral stimulation,17 ODN induced 
62% of pDC differentiation into P1 and P2, with no differ-
ences observed between healthy and SSc samples (figure 1D,E). 
In this context, BDCA2- targeting caused an increase of the P3 
subpopulation, which has been previously shown to produce less 
IFN.17 These data were further validated by performing FACS 
analysis of IFN- positive pDC gated within human PBMC (online 
supplemental figure S2B). Functionally, ODN led to a dramatic 
induction of IFN positive pDC, which was reduced by 76% with 
BDCA2- targeting (figure 1F,G).
Beyond type I IFN signature genes, ODN- induced inflamma-
tory interleukin (IL)-6 expression was also modulated by BDCA2- 
targeting. Interestingly, IL-6 and IFN secretion can synergistically 
activate B cells.17 43 Among other genes of interest, serglycin 
(SRGN) also showed a TLR- induced and BDCA2- dependent 
pattern. SRGN has been shown to be secreted into the extracellular 
matrix and linked to promoting lymphoid cells adhesion and acti-
vation,44 45 storage of chemokines and cytokines, as well as being 
able to induce epithelial–mesenchymal transition.46 47 These data 
demonstrate that TLR stimulation of human pDC goes beyond 
IFN secretion induction and predicts a greater biological relevance 
of pDC activation in IMID. Our analyses show that TLR- induced 
pDC activation can be drastically suppressed by BDCA2- targeting.
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Figure 1 TLR9- induced activation of human pDC goes beyond type I IFN secretion and is hindered by BDCA2- targeting in vitro. Transcriptome 
analysis of human pDC cultured in media alone (CTR), with 1 µM ODN2216 (ODN) or with ODN and CBS004 (10 µg/mL) (added 15 min prior to 
stimulation) for 16 hours (n=4). (A) Heatmap of reduced, centred normalised read counts for DE transcripts among CTR and ODN populations, <5% 
FDR, calculated using Benjamini- Hochberg multiple testing correction. DE transcripts≥or ≤2- fold (FDR<0.05) shown in online supplemental table 
1. (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showing top biological processes enriched in the set of DE transcripts 
between CTR and ODN pDC, and their associated p values. (C) Average fold change of DEGs for ODN and ODN+CBS004 relative to CTR (n=4). 
For repeat transcripts, the highest fold change was used for comparison. Red bars represent the 87 genes that were increased ≥2- fold (FDR<0.05) 
between CTR and ODN that are dependent on BDCA2 treatment (reduced ≥1.5- fold by CBS004) (full transcript data, online supplemental table 2). 
(D,E) Validation of CD274 (PD- L1) TLR- induced expression. (D) Example of subtyping FACS analysis of pDC (CD123+CD304+) in the three culture 
conditions (CTR, ODN and ODN+CBS004). Gating illustrates P1, P2 and P3 subtypes, with the former two previously shown to be IFN- secreting cells.17 
PBMC were cultured for 16 hours and pDC sorted as Lin-HLA- DR+CD45+CD123+CD304+ (online supplemental figure S2B) and gated for PD- L1 and 
CD80 expression to determine P1, P2 and P3 sub- types. P1, PD- L1+CD80−; P2, PD- L1+CD80+; P3, PD- L1-CD80+.17 (E) Quantification of sub- types based 
on FACS analysis of PBMC samples (healthy and SSc n=3, 4) between ODN and ODN+CBS004 culture conditions. (F,G) Validation of IFN- related gene 
expression. (F) Representative histogram of intracellular IFN alpha staining of pDC gated within PBMC when cultured in RPMI alone, with ODN (1 
µM) and with CBS004 (10 µg/mL). (G) Percentage of IFN- positive pDC from FACS analysis from F (n=6). (E,F) Error bars represent mean±SEM, and 
statistical significance was evaluated using paired two- tailed t- test. *P<0.05, **P<0.01. CTR, control; DE, differentially expressed; DEG, differentially 
expressed gene; FACS, fluorescence- activated cell sorting; FDR, false discovery rate; IFN, interferon; PBMC, peripheral blood mononuclear cell; pDC, 
plasmacytoid dendritic cell; SEM, standard error of mean; SSc, scleroderma.
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Human pDC induced IFN response in organotypic skin rafts 
(OSR), which is inhibited by BDCA2-targeting
Growing evidence shows pDC skin infiltration and induced IFN 
signature within the skin of patients with IMID, such as SSc.24–28 
Furthermore, PBMC- conditioned media are known to activate a 
proinflammatory response in fibroblasts.48 To determine whether 
TLR9- stimulated pDC could also induce this response, and whether 
treatment with CBS004 may have a functional effect on target tissue 
cell activation, we set out to measure IFN- induced genes in an OSR 
model of keratinocytes and fibroblasts co- culture following exposure 
to pDC supernatants (figure 2A).
First, we performed IFN secretion ELISA assays on pDC purified 
from PBMC (online supplemental figure S1) to establish the concen-
tration of IFN within ODN- stimulated pDC supernatants. ODN 
stimulation was for 16 hours to allow IFN secretion into the super-
natant to accumulate, since pDC–IFN maximum production has 
previously been shown between 12 and 18 hours.49 50 TLR9 induced 
a striking increase in IFN-α secretion. The addition of CBS004 15 
min prior to ODN stimulation suppressed this by 90%, whereas 
human IgG (HIgG) had no significant effect (figure 2B). To ensure 
functional inhibition driven by BDCA2- targeting of human pDC was 
maintained in HV and SSc PBMC, we conducted the same exper-
iment ex vivo. ODN stimulation of PBMC induced a similar but 
substantial increase in IFN secretion in HV and SSc samples, which 
again was suppressed by >98% in all samples by BDCA2- targeting 
(figure 2C). To determine the dose–response of CBS004 and to 
determine the concentration needed for maximal inhibition of IFN 
secretion, similar experiments were carried out on ODN- treated 
HV PBMC, identifying IC50 0.06 nM and IC90 0.86 nM values, 
with HIgG not effecting IFN production (figure 2D). The inhibi-
tory activity of CBS004 was 17- fold higher than previously tested 
mAb AC144, which supports the in vitro data showing enhanced 
BDCA2 affinity and binding (online supplemental figures S3A and 
S2A). Importantly, BDCA2- targeting did not significantly reduce 
pDC viability as determined by 7AAD assay gated within HV PBMC 
(online supplemental figures S2B, S3B).
OSR were treated with supernatants from pDC cultured in cell 
media alone (CTR), ODN or ODN+CBS004 (figure 2A,B). The 
volume of supernatant was calculated to produce a final concentra-
tion of 6000 pg/mL of IFN in the ODN experiment, as determined 
via ELISA (figure 2B). Real- time quantitative reverse transcription 
PCR (qRT- PCR) of 78 key interferon signalling genes (ISGs) was 
performed on RNA collected from the keratinocyte and fibroblast 
collagen matrix. ODN supernatants resulted in an increase of 1.8- 
fold to 32- fold in 35 ISGs relative to CTR (figure 2E). Despite the 
limited number of models tested (n=3), eight genes showed a statis-
tically significant upregulation, including ISG15, IFITM1, BST2, 
IFI6, IFIH1, NMI, HLA- B and IFITM3 (induction of 3- fold to 
19- fold relative to control and p<0.05). These data support the use 
of OSR to explore the effect of TLR- activated pDC in a preclinical 
human model. Importantly, ODN+CBS004 supernatants resulted 
in suppressed upregulation in all of those genes, ranging from 1.8- 
fold to 11- fold compared with gene expression induced by ODN 
(figure 2F; ANOVA, p<0.0001). This resulted in a transcription 
profile similar to CTR (figure 2G). Together these results suggest 
that BDCA2- targeting of pDC can suppress the IFN signature within 
skin cells.
Xenotransplant of human pDC in NOD SCID mice increased 
skin IFN response to TLR stimulation in a BDCA2-dependent 
manner
To advance our understanding of the role of circulating human 
pDC in IFN- induced response within the skin, we developed 
a novel in vivo model. We implemented a xenotransplant 
transfer of purified normal human primary pDC into nonobese 
diabetic/severe combined immunodeficiency (NOD SCID) mice 
(XenoSCID) via intravenous (iv) injection followed by topical 
application of imiquimod- containing cream (Aldara, TLR7 
agonist), with or without anti- BDCA2 (CBS004) or human IgG 
(HIgG) (online supplemental figure S4A). Topical imiquimod 
contains a TLR7 agonist that when applied to resting skin 
induces expression of type I IFN, primarily in macrophages.51 
Repeated application of topical imiquimod results in induction 
of ISG in an IFNAR1- dependent manner, the recruitment of 
leukocytes, skin thickening and the development of an inflam-
matory lesion. Xenotransplantation of human pDC into this 
model would allow us to determine pDC role in ISG response 
to imiquimod and whether it is sensitive to BDCA2- targeting. 
In vitro imiquimod- stimulation of healthy PBMC induced IFN 
secretion, which was BDCA2- dependent (online supplemental 
figure S4B). The purity of pDC isolated from healthy PBMC 
for in vivo experiments and functional responses to TLR-9 were 
assessed (online supplemental figures S1, S4C). FACS analysis 
of CD45+CD123+CD304+cells indicated pDC skin infiltra-
tion within the Aldara+pDC condition (0.3% of total cells, 
figure 3A), which resulted in a functional increase in mouse 
skin ISG expression, as mice receiving human pDC induced a 
3.2- fold increase in composite ISG score (including Ifit1, Isg15, 
Mx1, Cxcl10 and Viperin), compared to CTR (ANOVA P<0.05) 
(figure 3B). Importantly, this is greater than Aldara treatment 
alone in absence of pDC, where a 1.7- fold increase in composite 
ISG score compared to CTR was observed (figure 3B). In agree-
ment, IHC staining showed only a slight increase in MX1 protein 
expression levels between CTR and Aldara (online supplemental 
figure S4D). Interestingly, epidermal thickening was observed 
(online supplemental figure S4D), which has previously been 
shown be an Aldara- induced response independent of type I IFN 
and TLR7.38
In this context, we could assess the in vivo efficacy of BDCA2- 
targeting. CBS004 and HIgG control mAb were injected into 
XenoSCID 12 hours before pDC intravenous injection (online 
supplemental figure S4A). Aldara- induced pDC skin infiltra-
tion, as detected by human CD45+CD123+CD304+ cells in 
the mouse treated skin, was not hindered by HIgG (0.3% of 
total cells) but reduced 3- fold by BDCA2- targeting (figure 3C). 
Most importantly, BDCA2- targeting suppressed 44% of the ISG 
expression observed in Aldara+pDC, which was significantly 
reduced compared with HIgG administration (figure 3D).
Consistent with these findings, immunohistochemistry (IHC) 
analysis showed a strong induction of MX1 and pSTAT1 
(Tyr701) with pDC transplantation compared with NOD SCID 
mice, which was dramatically reduced by BDCA2- targeting and 
unaffected by HIgG (figure 3E,F).
Xenotransplant of human pDC in NOD SCID mice increased 
the skin profibrotic response to bleomycin treatment in a 
BDCA2-dependent manner
Ah Kioon et al have shown that depletion of mouse pDC can 
ameliorate bleomycin- induced skin fibrosis in a mouse model 
of SSc.24 While supporting the role of pDC in fibrosis in mice, 
the model could not directly demonstrate the role of human 
pDC in this setting. Thus, we developed our XenoSCID model 
with bleomycin- induced skin fibrosis. We supplemented every 
other day subcutaneous injection of bleomycin with weekly tail 
vein injection of human pDC for 3 weeks (online supplemental 
figure S5A). As anticipated in an immunocompromised mouse, 
bleomycin alone induced a blunted fibrotic response at 3 weeks, 
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Figure 2 Human pDC induced IFN response in OSR, which is suppressed by BDCA2- targeting. (A) Systematic outline of OSR protocol; fibroblasts 
are embedded into a collagen matrix and keratinocytes seeded above until confluence. OSR is brought to ALI to sustain epithelium differentiation. 
After 5 days, ALI media spiked with 6000 pg/mL of IFN (generated by TLR- stimulated pDC, ODN (B)) for 48 hours. CTR contains equivalent supernatant 
from untreated pDC (undetectable IFN) and from pDC treated with ODN+CBS004 (10 µg/mL). (B) Quantification of IFN secretion from purified HV 
pDC (n=7) after 16 hours of culturing in cell media alone (CTR), with ODN (1 µM) and with CBS004 or human IgG1 (10 µg/mL) (added 15 min prior 
to stimulation) measured by ELISA to determine volume to add to ALI. (C) CBS004 suppresses TLR- induced IFN secretion in HV and SSc PBMC. PBMC 
from donors were cultured in media alone (CTR), with 1 µM ODN, or with ODN and CBS004 [10 µg/mL] for 16 hours (n=15). IFN was quantified in 
the supernatants by ELISA. (B,C) Error bars represent mean±SEM and statistical significance was evaluated using unpaired two- tailed t- test. (D) 
Percentage of IFN alpha secretion, measured by ELISA, from PBMC from four donors stimulated with ODN in the presence of CBS004 or HIgG (0–66 
nM) relative to ODN- stimulated pDC with no antibody (100%). Dotted lines highlight IC50s and IC90 with mean values±SEM. (E,F) RNAs harvested 
from 3 mm biopsies from OSR and subjected to type I IFN inducible genes superarray. Volcano plots illustrate the fold change of 79 IFN type I- related 
genes (black dots) between CTR and ODN (E) and between ODN and ODN+CBS004 (F) (pDC supernatant from three different donors for each 
condition). Grey lines represent the 1.8- fold change cut- off. The blue line represents the cut- off for statistical significance of p=0.05 calculated using 
Student’s t- test (two- tailed distribution and equal variances between the two samples) on the triplicate 2−ΔCt values for each gene in each treatment 
group compared with the CTR group. (F) bar chart illustrates the IFN type I- related genes that were >1.8 fold increased in ODN relative CTR and the 
effect of CBS004. results are represented as means±SEM. *P<0.05, ***P<0.001. ALI, air–liquid interface; CTR, control; HIgG, human IgG; HV, healthy 
volunteer; IFN, interferon; OSR, organotypic skin raft; PBMC, peripheral blood mononuclear cell; pDC, plasmacytoid dendritic cell; SEM, standard error 
of mean; SSc, scleroderma.
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Figure 3 XenoSCID with human pDC increased skin IFN response to TLR stimulation in a BDCA2- dependent manner. Intravenous tail injection of 
2.5×105 human purified pDC and intraperitoneal injection of CBS004 mAb (5 mg/kg) or CTR human IgG to NOD SCID mice treated with topical Aldara 
cream application (online supplemental figure S4A, systematic diagram and timeline), with five different treatment conditions consisting of CTR (n=5), 
Aldara (n=5), Aldara+pDC (n=5), Aldara+pDC+CBS004 (n=9) and Aldara+pDC+HIgG (n=9). Treated skin was harvested using a 3 mm punch biopsy 
and processed for FACS analysis of human pDC (CD45+CD123+CD304+) (representative analyses A and C), qRT- PCR analysis for type I IFN inducible 
genes (B,D), and IHC staining for MX1 and pSTAT1 (Tyr701) (E,F). (B) Composite ISG score within Aldara and Aldara+pDC conditions relative to CTR. 
Score shows average fold difference between relative expression of Mx1, Isg15, Cxcl10, Ifit1, Isg15 and Viperin between the test condition and CTR. 
Different symbols represent the different mice litters/human pDC donors. Statistical significance was evaluated using analysis of variance test. (D) 
Illustration of the composite ISG scores for +CBS004 and +HIgG conditions relative to that of Aldara+pDC. Statistical significance was evaluated 
using unpaired two- tailed t- test, *P<0.05, **P<0.01. CTR, control; HIgG, human IgG; IHC, immunohistochemistry; ISG, interferon signalling gene; NOD 
SCID, nonobese diabetic severe combined immunodeficiency; pDC, plasmacytoid dendritic cell; qRT- PCR, real- time quantitative reverse transcription 
PCR; NOD SCID.
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Figure 4 XenoSCID with human pDC increased the pro- fibrotic skin response to bleomycin treatment in a BDCA2- dependent manner. Intravenous 
tail injection of 2.5×105 human purified pDC and intraperitoneal injection of CBS004 mAb (5 mg/kg) or CTR human IgG into NOD SCID mice 
treated with Bleo or PBS injections (online supplemental figure S5A); systematic diagram and timeline, with five different treatment conditions 
consisting of PBS/CTR, Bleo, Bleo+pDC, Bleo+pDC+CBS004 and Bleo+pDC+HIgG, each in triplicate. Treated skin was harvested using a 3 mm punch 
biopsy and processed for H&E (A) and MT staining (B). (C) Epidermis and dermal thickness were measured from 20 areas in each condition. (D) An 
additional punch biopsy was taken and used to extract protein. Total collagen content measured by SircolTM assay and shown relative to total protein 
concentration. Results represented as means±SEM of triplicate experiments. Statistical significance was evaluated using paired two- tailed t- test. (E,F) 
IHC analysis of MX1 and pSTAT1 (Tyr701) representative images with zoomed in areas, arrows highlight positively stained cells. *P<0.05, **P<0.01, 
***P<0.001. Bleo, bleomycin; CTR, control; HIgG, human IgG; IHC, immunohistochemistry; MT, Masson trichrome; NS, no significance; NOD SCID, 
nonobese diabetic severe combined immunodeficiency; PBS, phosphate buffered saline; pDC, plasmacytoid dendritic cell; SEM, standard error of mean.
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as shown by partially retained fatty layer, as well as no signifi-
cant differences observed in skin thickness and collagen content 
compared with control (figure 4A–D). Furthermore, no signifi-
cant increase in MX1 protein expression was observed (online 
supplemental figure S5B,C). Injection of human pDC resulted in 
bleomycin- induced loss of all subdermal fat, along with increased 
collagen formation and a 40% increase in overall skin thickness 
(figure 4A–D). The fibrotic response was associated with type I 
IFN signalling activation as MX1 and pSTAT1 (Tyr701) protein 
expression was increased (figure 4E,F and online supplemental 
figure S5B,C).
To determine the therapeutic implications of BDCA2- targeting, 
bleomycin- XenoSCID were treated with intraperitoneal injec-
tion of CBS004 or HIgG (online supplemental figure S5A). 
pDC- induced skin fibrosis was dramatically reduced by BDCA2- 
targeting as demonstrated by the retention of some fatty layer 
tissue, similar to bleomycin- only treated mice, a 2- fold reduction 
in dermal and epidermal thicknesses and 1.5- fold reduction in 
collagen content compared with HIgG (figure 4A–D). Further-
more, reduction in MX1 and specific pSTAT1 dermal fibro-
blast (based on morphology) protein expression was observed 
compared with HIgG treatment (figure 4E,F and online supple-
mental figure S5B,C).
Overall, our xenotransplant models clearly show that human 
pDC have a crucial and direct role in skin inflammation and 
fibrosis and highlight pDC as a viable therapeutic target for SSc.
DISCUSSION
In the past decade, substantial evidence has pointed to the 
involvement of pDC in the pathogenesis of many IMID, including 
SSc.24–28 Nevertheless, research on pDC has focused only on 
indirect evidence using ex vivo human samples or mouse models. 
A recent key study supports that mouse pDC have a pathogenic 
role in fibrosis, as pDC depletion reduced bleomycin- induced 
IFN- I stimulated transcripts and prevented fibrosis.24 Due to key 
differences between mouse and human pDC, functions deter-
mined in mouse models may not be fully transferable to human 
pDC.13 37–39 In our study, we overcame these challenges by 
implementing novel preclinical models of human pDC function 
in vitro and in vivo. The development of our xenograft models 
has allowed for the first time to study the role of circulating 
human pDC within inflammation and fibrosis. Furthermore, by 
using CBS004, we were able to study the efficacy of specifically 
attenuating human pDC function by BDCA2- targeting.
Our study shows that TLR stimulation of pDC activates a gene 
expression profile mapping to activation of inflammation, JAK/
STAT, NF- kB and angiogenesis pathways, predicting a greater 
biological relevance of pDC activation in IMID. A time course of 
ODN stimulation would be beneficial in the future to determine 
the transcriptome over time and to ensure key gene expression 
has not been overshadowed, as well as determining the effect of 
restimulation of previously stimulated pDC.50 Crucially, we have 
shown that BDCA2- targeting is effective at blocking pDC IFN 
production, as well as the ODN- induced transcriptome. Further-
more, we show that BDCA2- targeting strongly suppresses the 
differentiation of IFN- secreting CD274+ pDC17 with a preva-
lent differentiation towards CD274−CD80+ pDC. Further func-
tional studies will shed light on the effects of BDCA2- targeting 
on T- cell costimulation, which has been suggested to be affected 
by CD274−CD80+ pDC.17
Our preclinical organotypic model of human skin allowed us 
to show target cell activation by TLR- activated pDC and further 
supports the biological relevance of BDCA2 inhibition. Our 
XenoSCID model using human pDC greatly expanded this obser-
vation. By inducing local TLR- activated skin, we have shown that 
human pDC can migrate efficiently into Aldara- treated skin and 
enhance mouse IFN response, as seen in patients with SSc.24–28 
Aldara treatment alone increased a small increase in mouse IFN 
skin response. pDC can be found in mouse blood and lymphoid 
tissue of NOD SCID mice but are undetectable in skin biopsies 
either at rest or following imiquimod application for 24 hours,51 
indicating our observations are unlikely to be caused by host 
pDC. Furthermore, we clearly see that human pDC are capable 
of inducing IFN and fibrotic skin response when introduced into 
our bleomycin mouse model. While these data directly support 
a pro- fibrotic effect of pDC in response to bleomycin, they do 
not directly show that IFN is driving this effect. As shown in our 
in vitro data, pDC produce other cytokines that could plausibly 
drive the tissue fibrosis in this model. Nevertheless, BDAC2- 
targeting of pDC in situ prevented the pathogenic responses to 
proinflammatory and pro- fibrotic stimuli, identifying specific 
pDC targeting to be a viable therapeutic application for SSc. Our 
data are supported by similar observations seen when mouse 
pDC were depleted in a bleomycin- induced fibrotic model of 
SSc and when specific BDCA2- targeting of resident human pDC 
in a xenograft Psoriasis model prevented progression into psori-
atic skin.19 24 52
The development of our XenoSCID model is a novel tool 
that can be used to study the biology of human pDC in mice 
and can be applied in the research of other IMID affecting the 
skin, such as psoriasis or SLE. A limitation of this approach 
is the lack of adaptive immune response in these animals. 
Therefore, the consequence of pDC inhibition in a competent 
immune system remains unknown. Nevertheless, the studies 
from Rowland et al showed that in a mouse model of SLE, 
elimination of pDC strongly impaired expansion and activa-
tion of T and B cells.21 In this context, xenotransplant models 
of human PBMC with and without pDC depletion would be 
extremely informative although falling beyond the scope of 
this study.
Together, our data indicate that human pDC, and their cyto-
kine production, are a key cell type in the pathogenesis of SSc. 
As shown in our in vitro and in vivo models, BDCA2- targeting of 
human pDC can reduce ISG response and inflammation, as well 
as prevent fibrosis. For effective therapeutic application, strati-
fication of patients for those with pDC infiltration and higher 
IFN score should aid responsiveness to BDCA2 suppression of 
fibrosis.
MATERIAL AND METHODS
Detailed description of experimental methods is available in 
online supplemental file 1.
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